Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers

NCT04712877 is registered in ClinicalTrials.gov with Lung Cancer Mutation Consortium as lead sponsor.

NCT NCT04712877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04712877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
Lead sponsor
Lung Cancer Mutation Consortium
Phase
Observational
Overall status
Unknown status
Start date
June 15, 2022
Completion date
June 15, 2026
Enrollment
1,000 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc